Replies to post #158198 on Biotech Values

[DewDiligence]

XOMA is full- funded through the end of 2014 and all three Ph3 Eyeguard read-outs.

I take the company’s assertion with a grain of salt insofar as the projected cash balance at the end of 2013 will be in the neighborhood of $30M.

If Eyeguard-A data is positive, I suspect they'll use the opportunity to raise $'s in front of what would then be the pivotal Eyeguard-C data.

Agreed.